Optimizing migraine therapy: Evidence-based and patient-centered care

Expert Review of Neurotherapeutics

Volumn 6, Issue 6, 2006, Pages 911-919

  Diamond, Merle L ^a   Wenzel, Richard G ^a   Nissan, George R ^a,b  

^a DIAMOND HEADACHE CLINIC   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Evidence based care; Migraine; Stratified care

Indexed keywords

ANTIEMETIC AGENT; CAFFEINE; CODEINE; DIHYDROERGOTAMINE; ELETRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE;

DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDUCATION; EVIDENCE BASED MEDICINE; HEALTH CARE PERSONNEL; HUMAN; LIFESTYLE; MIGRAINE; PATIENT CARE; REVIEW;

EVIDENCE-BASED MEDICINE; HUMANS; MIGRAINE DISORDERS; PATIENT-CENTERED CARE;

EID: 33745501800     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.6.911     Document Type: Review

References (56)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd Edition. Cephalalgia 24(Suppl. 1), 1-151 (2004).
2. Lipton RB, Bigal ME. The epidemiology of migraine. Am. J. Med. 118(Suppl. 1), S3-S10 (2005).
3. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability, and Health. J. Headache Pain 6, 429-440 (2005).
4. Cady R, Schrieber C, Farmer K, Sheftell F. Primary headaches: a convergence hypothesis. Headache 42, 204-216 (2002).
5. Lipton RB, Scher AI, Kolodner K et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology 58, 885-894 (2002).
6. Lipton RB, Diamond SD, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41, 638-645 (2001).
7. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA 267, 64-69 (1992).
8. Osterhaus JT, Guterman DI, Planchetka JR. Healthcare resources and lost labor costs of migraine headache in the U.S. Pharmcol. Econ. 2, 67-76 (1992).
9. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 159, 813-838 (1999).
10. Kaniecki RG. The impact of migraine: how this disorder affects us all. Consultant 40, S25-S28 (2000).
11. WHO. Headache disorders and public health. Geneva, Switzerland: Department of Mental Health and Substance Dependence, Noncommunicable Diseases and Mental Health Cluster, WHO (2000).
12. Lipton RB, Bigal ME, Amatniek JC, Stewart WF. Tools for diagnosing migraine and measuring its severity. Headache 44, 387-398 (2004).
13. Holroyd KA, Cordingley GE, Pingel JD et al. Enhancing the effectiveness of abortive therapy: a controlled evaluation of self-management training. Headache 29, 148-153 (1989).
14. Blumenfeld A, Tischio M. Center of excellence for headache care: group model at Kaiser Permanente. Headache 43, 431-440.
15. Marcus DA. Establishing a standard of speed for assessing the efficacy of serotonin agonists. Arch. Neurol. 58, 1056-1058 (2001).
16. Santanello NC, Davies G, Allen C, Kramer M, Lipton R. Determinants of migraine-specific quality of life. Cephalalagia 22, 680-685 (2002).
17. Diener HC, Brune K, Gerber WD, Gobel H, Pfaffenrath V. Treatment of migraine attacks and migraine prophylaxis: recommendations of the German Migraine and Headache Society. Med. Monatsschr. Pharm. 21, 30-39 (1998).
18. No author listed. Guidelines for the management of headache. Danish Neurological Society and the Danish Headache Society. Cephalalgia 18, 9-22 (1998).
19. Ducharme J. Canandian Association of Emergency Physician Guidelines for the acute management of migraine headache. J. Emerg. Med. 17, 137-144 (1999).
20. Geraud G, Lanteri-Minet M, Lucas C, Valade D. French guidelines for the diagnosis and management of migraine in adults and children. Clin. Ther. 26, 1305-1318 (2004).
21. No author listed. Guidelines for the treatment of migraine crisis. Concensus of the Sociedade Brasileira de Cefaleia. Ad Hoc Committee. Arq. Neuropsiquiatr. 58, 371-389 (2000).
22. Silberstein SD, for the US Headache Consortium. Practice parameter: evidencebased guidelines for migraine headache. Neurology 55, 754-762 (2003).
23. Devine JW, Farley JF, Hadsall RS. Patterns and predictors of prescription medication use in the management of headache: findings from the 2000 Medical Expenditure Panel Survey. Headache 45, 1171-1180 (2000).
24. Gladstone JP, Gawel M. Newer formulations of the triptans: advances in migraine management. Drugs 63, 2285-2305 (2003).
25. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Triptans in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001).
26. Dodick D, Lipton RB, Martin V et al. Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44, 414-425 (2004).
27. Glaxo SmithKline. Imitrex (sumatriptan) prescribing information. Research Triangle Park, NC (2001).
28. GlaxoSmithKline. Amerge (naratriptan) prescribing information. Research Triangle Park, NC (2001).
29. AstraZeneca Pharmaceuticals LP. Zomig (zolmitriptan) prescribing information. Wilmington DE (2001).
30. Merck and Co. Maxalt (rizatriptan) prescribing information. West Point, PA (2001).
31. Endo Pharmaceuticals. Frova (frovatriptan) prescribing information. Chadds Ford, PA (2004).
32. Ortho-McNeil Neurologics, Inc. Axert (almotriptan) prescribing information. Titusville, NJ (2004).
33. Pfizer Inc. Relpax (eletriptan) prescribing information. New York, NY (2005).
34. Dodick DW, Silberstein S, Dahlof CG. Is there a preferred triptan? Headache 42(1), 1-7 (2002).
35. Pringsheim T, Gawel M. Triptans: are they all the same? Curr. Pain Headache Rep. 6(2), 140-146 (2002).
36. Saper J. What matters is not the difference between the triptans, but the differences between patients. Arch. Neurol. 58, 1481-1482 (2001).
37. Geraud G, Olesen J, Pfaffenrath V et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 20(1), 30-38 (2000).
38. Mathew NT, Loder EW. Evaluating the triptans. Am. J. Med. 118(Suppl. 1), S28-S35 (2005).
39. Lipton RB, Stewart WF. What do migraineurs want? Headache 39(Suppl. 2), S20-S26 (1999).
40. Wenzel RG, Sarvis CA, Krause ML. Overthe-counter drugs for acute migraine attacks: literature review and recommendations. Pharmacotherapy 23, 494-505 (2003).
41. Gray RN, McCrory DC, Eberlein K et al. Self-administered Drug treatments for acute migraine headache. Technical review 2.4. Prepared by the Agency for Health Care Policy and Research under Contract No. 290-94-2025. Available from the National Technical Information Service. NTIS Accession No. 127854. Duke University Center for Clinical Health Policy Research; Durham, NC (1999).
42. Pfaffenrath V, Scherzer S. Analgesics and nsaids in the treatment of acute migraine attack. Cephalagia 15(Suppl. 15), 14-20 (1995).
43. Loder E. Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs 19(9), 769-784 (1995).
44. Wenzel RG, Sarvis CA. Do butalbitalcontaining products have a role in the management of migraine? Pharmacotherapy 22, 1029-1035 (2002).
45. Young WB, Siow HC. Should butalbitalcontaining analgesics be banned? Yes. Curr. Pain Headache Rep. 6, 151-155 (2002).
46. Richard B. Lipton RB, Bigal ME. Opioid therapy and headache: a cause and a cure. Neurology 62, 1662-1663 (2004).
47. Saper JR, Lake AE 3rd, Hamel RL et al. Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. Neurology 62, 1687-1694 (2004).
48. Diamond S, Diamond ML, Silberstein S. Winner P. Advances in migraine management: the roles of acute, prophylactic, and rescue medications. Headache Quarterly 12, 183-194 (2001).
49. Lipton RB, Stewart WF, Stone Am, Lainez JHA, Sawyer JPC. Stratified care versus step care for migraine. JAMA 284, 2599-2605 (2000).
50. Wenzel R. Triptan quantity limits. J. Managed Care Pharmacy 8(3), 182-184 (2005).
51. Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: the Disability in Strategies for Care (DISC) Study. Pharmacoeconomics 20, 91-100 (2002).
52. Williams P, Dowson AJ, Rapoport AM, Sawyer J. The cost-effectiveness of stratified care in the management of migraine. Pharmacoeconomics 19, 819-829 (2001).
53. Bigal ME, Rapoport AM, Bordini CA, Tepper SJ, Sheftell FD, Speciali JG. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache 43, 742-754 (2001).
54. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106(1-2), 81-89 (2003).
55. Wenzel RG, Schwartz C, Pariyara RA. Topiramate for migraine prevention: a literature review. Pharmacotherapy 26, 375-387 (2006).
56. Holroyd KA, France JL, Cordingley GE et al. Enhancing the effectiveness of relaxation-thermal biofeedback training with propranolol hydrochloride. J. Consult Clin. Psychol. 63, 327-330 (1995).